- Policy
- Ex officio adjustment reduces prices of Faslodex and Acelex
- by Kim, Jung-Ju Nov 8, 2022 05:43am
- AstraZeneca Faslodex and Crystal Genomics Acelex will receive a 30% discount due to the government's authority adjustment. They are expected to fall 23.5% each in the second half of next year when the addition ends. Roflumilast formulations such as Sama Roflu 500μg and AstraZeneca Daxas 500μg of Korea, which has been receiving additional asset
- Policy
- It has been four years since Eucept was released
- by Lee, Hye-Kyung Nov 7, 2022 06:06am
- The permission of LG Chem's rheumatoid arthritis treatment Eucept (Etanercept) will be changed. The MFDS will prepare an order (proposal) to change the permission items based on the results of the re-examination of Eucept Prefilled Syringe and Eucept Auto Injector and inquire about opinions until the 17th. Eucept is LG Chem's first antibody-
- Policy
- We will continue to strengthen cooperation with the HIRA
- by Kim, Jung-Ju Nov 7, 2022 06:05am
- The HIRA (Director Kim Sun-min) announced on the 4th that Rudi Eggers, director of the World Health Organization (WHO) Integrated Health Services (IHS), visited the HIRA to discuss international cooperation measures. Under the agreement with the WHO, the HIRA has been sending screening and evaluation experts to the WHO Integrated Health S
- Policy
- No budget set to compensate increasing Paxlovid AE reports
- by Lee, Jeong-Hwan Nov 7, 2022 06:05am
- It has been found that no government budget has been set to compensate for the adverse events that may occur after receiving COVID-19 treatments granted emergency use authorizations in Korea. Therefore, a claim has been raised that a supplementary budget needs to be set to review and provide damage relief from the use of EUA drugs that d
- Policy
- Strepto formulations negotiated at a rate of 20%
- by Lee, Tak-Sun Nov 4, 2022 05:39am
- The pharmaceutical industry has low drug prices, so if the recovery rate is more than 20%, there is no margin left Based on the results of the clinical re-evaluation of the anti-inflammatory enzyme drugs Streptokinase and Streptodornase, the NHIS and pharmaceutical companies, which have started negotiations to recover their salaries, are r
- Policy
- Government-Pharmaceutical Consultation on Acetaminophen
- by Lee, Jeong-Hwan Nov 4, 2022 05:39am
- The Ministry of Health and Welfare met with domestic and foreign pharmaceutical companies to cooperate to increase production and facilitate distribution of cold medicine Acetaminophen 650 mg, and actively promote necessary institutional support such as raising the price of drugs. Park Min-soo, the second vice minister of the Ministry of Heal
- Policy
- Reimb standards set for first RET-targeted Retevmo
- by Lee, Tak-Sun Nov 4, 2022 05:39am
- Reimbursement listing for Lilly’s ‘Retevmo cap(selpercatinib),’ the first RET-targeted anticancer therapy in Korea, is gaining speed after successfully setting reimbursement standards. As the drug is eligible for expedited listing in Korea as a treatment used for life-threatening conditions, its time to reimbursement listing is expect
- Policy
- The self-sufficiency of national essential drugs has begun
- by Lee, Hye-Kyung Nov 4, 2022 05:38am
- The selection of 11 candidate medicines that require the development of domestic manufacturing and quality evaluation technologies has been completed. The Ministry of Food and Drug Safety recently selected a total of 11 items (5 raw materials & 6 finished products) as the first stage of development candidates after deliberation by the Product Se
- Policy
- Akynzeo is licensed domestically
- by Kim, Jung-Ju Nov 3, 2022 05:54am
- The Ministry of Food and Drug Safety has landed in Korea with new drug imported by HK inno.N. The Ministry of Food and Drug Safety (Director Oh Yoo-kyung) approved Akynzeo, an imported new drug of HKinno.N, on the 31st, which prevents nausea and vomiting caused by the administration of chemotherapy drugs. This is a drug for preventing acute a
- Policy
- NHI big data was used to evaluate safety of JAK inhibitors
- by Lee, Tak-Sun Nov 2, 2022 05:36am
- Big data from the National Health Insurance was found to have been used to evaluate the safety of JAK inhibitors, based on which its use has been restricted in high-risk patients in Korea. This is the first time that NHI big data had been used for safety evaluation of pharmaceuticals in Korea. The National Health Insurance Service’s Big
